NAS:FATE (USA) Also Trade In: Germany

Fate Therapeutics Inc $ 47.46 0.56 (1.19%)

Volume:
591,850
Avg Vol (1m):
999,401
Market Cap $:
4.12 Bil
Enterprise Value $:
3.67 Bil
P/E (TTM):
0.00
P/B:
8.71
Warning! GuruFocus has detected 3 Severe warning signs with FATE. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for FATE (Fate Therapeutics Inc) from 2013 to Oct 27 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Fate Therapeutics stock (FATE) PE ratio as of Oct 27 2020 is 0. More Details

Fate Therapeutics PE Ratio (TTM) Chart

EMBED

Fate Therapeutics PE Ratio (TTM) Historical Data

Total 1256
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Fate Therapeutics PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2020-10-270.0 2020-08-250.0
2020-10-260.0 2020-08-240.0
2020-10-230.0 2020-08-210.0
2020-10-220.0 2020-08-200.0
2020-10-210.0 2020-08-190.0
2020-10-200.0 2020-08-180.0
2020-10-190.0 2020-08-170.0
2020-10-160.0 2020-08-140.0
2020-10-150.0 2020-08-130.0
2020-10-140.0 2020-08-120.0
2020-10-130.0 2020-08-110.0
2020-10-120.0 2020-08-100.0
2020-10-090.0 2020-08-070.0
2020-10-080.0 2020-08-060.0
2020-10-070.0 2020-08-050.0
2020-10-060.0 2020-08-040.0
2020-10-050.0 2020-08-030.0
2020-10-020.0 2020-07-310.0
2020-10-010.0 2020-07-300.0
2020-09-300.0 2020-07-290.0
2020-09-290.0 2020-07-280.0
2020-09-280.0 2020-07-270.0
2020-09-250.0 2020-07-240.0
2020-09-240.0 2020-07-230.0
2020-09-230.0 2020-07-220.0
2020-09-220.0 2020-07-210.0
2020-09-210.0 2020-07-200.0
2020-09-180.0 2020-07-170.0
2020-09-170.0 2020-07-160.0
2020-09-160.0 2020-07-150.0
2020-09-150.0 2020-07-140.0
2020-09-140.0 2020-07-130.0
2020-09-110.0 2020-07-100.0
2020-09-100.0 2020-07-090.0
2020-09-090.0 2020-07-080.0
2020-09-080.0 2020-07-070.0
2020-09-070.0 2020-07-060.0
2020-09-040.0 2020-07-030.0
2020-09-030.0 2020-07-020.0
2020-09-020.0 2020-07-010.0
2020-09-010.0 2020-06-300.0
2020-08-310.0 2020-06-290.0
2020-08-280.0 2020-06-260.0
2020-08-270.0 2020-06-250.0
2020-08-260.0 2020-06-240.0

Fate Therapeutics PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Industry Healthcare » Biotechnology » NAICS : 325412 NAICS : 2836
Traded in other countries F6T.Germany FATE.USA
Address 3535 General Atomics Court, Suite 200, San Diego, CA, USA, 92121
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.